My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

11.87 +0.25 (+2.15%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing ↗

March 02, 2023

The FDA made a bold move in the CRISPR gene-editing realm.

Via Investor's Business Daily

Intellia Therapeutics Earnings Perspective: Return On Capital Employed ↗

February 28, 2023

Via Benzinga

Better Buy: Beam Therapeutics or Intellia Therapeutics? ↗

February 22, 2023

The two clinical-stage gene-editing companies have good long-term prospects.

Via The Motley Fool

3 Deeply Undervalued Stocks That Could Double Your Money ↗

February 15, 2023

These cutting-edge biotech stocks hold tremendous upside potential.

Via The Motley Fool

Top CRISPR Stocks ↗

February 11, 2023

CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses.

Via Talk Markets

3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street ↗

February 07, 2023

These stocks are risky. But they just might deliver huge gains if analysts are right.

Via The Motley Fool

Expert Ratings for Intellia Therapeutics ↗

January 24, 2023

Via Benzinga

The Latest Analyst Ratings for Intellia Therapeutics ↗

January 04, 2023

Via Benzinga

Analyst Ratings for Intellia Therapeutics ↗

December 02, 2022

Via Benzinga

Intellia's Hereditary Angioedema Candidate Shows Reduction In Associated Biomarkers, Attack Rates ↗

November 14, 2022

Via Benzinga

Earnings Scheduled For February 23, 2023 ↗

February 23, 2023

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

Via Benzinga

3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129% ↗

February 06, 2023

Cathie Wood is bullish about these stocks. And so are Wall Street analysts.

Via The Motley Fool

When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader? ↗

February 05, 2023

A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?

Via Talk Markets

Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock ↗

February 01, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023 ↗

February 01, 2023

Via Benzinga

Recap: Intellia Therapeutics Q3 Earnings ↗

November 03, 2022

Intellia Therapeutics (NASDAQ:NTLA) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

7 CRISPR Stocks With the Best Long-Term Potential ↗

January 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Via InvestorPlace

3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later ↗

January 25, 2023

Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.

Via InvestorPlace

3 Gene Editing Stocks With the Best Long-Term Potential ↗

January 25, 2023

These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space

Via InvestorPlace

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

January 24, 2023

The growth-focused money manager is making moves.

Via The Motley Fool

Stocks That Hit 52-Week Lows On Friday ↗

January 20, 2023

Friday saw 23 companies set new 52-week lows.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023 ↗

January 24, 2023

Via Benzinga

2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years ↗

January 07, 2023

Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023 ↗

January 19, 2023

Via Benzinga

1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now) ↗

December 30, 2022

Both stocks have fallen brutally this year, but only one has a chance to recover soon.

Via The Motley Fool

7 ‘Next Big Things’ for Investors to Buy for 2023 ↗

December 13, 2022

The next big thing for investors in 2023 is buying companies with revenue expansion amid what could be a painful economic slowdown.

Via InvestorPlace

Ulta Beauty To Rally Around 22%? Here Are 10 Other Price Target Changes For Friday ↗

December 02, 2022

Via Benzinga

NTLA Stock Falls as Intellia Therapeutics Announces Public Offering ↗

December 01, 2022

Intellia Therapeutics (NTLA) stock is falling hard on Thursday after the company announced a public stock offering of 6.6 million shares.

Via InvestorPlace

Cathie Wood Has Bet Big On These 10 Stocks; Here's How They're Performing ↗

November 28, 2022

Here's how Ark Invest's top holdings have performed in 2022.

Via Investor's Business Daily

Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94% ↗

November 15, 2022

Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday.

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.